Optiver Holding B.V. Calliditas Therapeutics Ab Transaction History

Optiver Holding B.V.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$17.65 - $41.41 $349,505 - $820,000	19,802 Added 781.45%	22,336 $870,000
Q1 2024 May 09, 2024	BUY	$20.04 - $25.66 $31,142 - $39,875	1,554 Added 158.57%	2,534 $53,000
Q4 2023 Feb 13, 2024	BUY	$15.79 - $28.99 $15,474 - $28,410	980 New	980 $25,000
Q2 2023 Aug 10, 2023	BUY	$15.7 - $25.61 $15 - $25	1 Added 0.02%	5,030 $79,000
Q1 2023 May 11, 2023	SELL	$16.8 - $25.24 $102,681 - $154,266	-6,112 Reduced 54.86%	5,029 $120,000
Q4 2022 Feb 10, 2023	SELL	$11.5 - $19.6 $17,066 - $29,086	-1,484 Reduced 11.75%	11,141 $189,000
Q3 2022 Nov 14, 2022	BUY	$14.12 - $22.49 $165,571 - $263,717	11,726 Added 1304.34%	12,625 $191,000
Q2 2022 Aug 10, 2022	BUY	$12.85 - $20.36 $7,144 - $11,320	556 Added 162.1%	899 $16,000
Q1 2022 May 16, 2022	SELL	$15.14 - $25.55 $633,730 - $1.07 Million	-41,858 Reduced 99.19%	343 $6,000
Q4 2021 Feb 14, 2022	BUY	$15.04 - $26.32 $633,138 - $1.11 Million	42,097 Added 40477.88%	42,201 $1.04 Million
Q3 2021 Nov 15, 2021	BUY	$21.03 - $33.19 $2,187 - $3,451	104 New	104 $2,000

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Optiver Holding B.V., based on Form 13F filings with the SEC.

Stay updated on Optiver Holding B.V. with notifications on news.